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Abstract
Cannabis is widely used for both recreational and medicinal purposes on a global scale. There is accumulating interest in the 
use of cannabis and its constituents for athletic recovery, and in some instances, performance. Amidst speculation of potential 
beneficial applications, the effects of cannabis and its two most abundant constituents, delta-9-tetrahydrocannabinol (THC) 
and cannabidiol (CBD), remain largely un-investigated. The purpose of this review is to critically evaluate the literature 
describing the effects of whole cannabis, THC, and CBD, on athletic performance and recovery. While investigations of whole 
cannabis and THC have generally shown either null or detrimental effects on exercise performance in strength and aerobic-
type activities, studies of sufficient rigor and validity to conclusively declare ergogenic or ergolytic potential in athletes are 
lacking. The ability of cannabis and THC to perturb cardiovascular homeostasis warrants further investigation regarding 
mechanisms by which performance may be affected across different exercise modalities and energetic demands. In contrast 
to cannabis and THC, CBD has largely been scrutinized for its potential to aid in recovery. The beneficial effects of CBD 
on sleep quality, pain, and mild traumatic brain injury may be of particular interest to certain athletes. However, research in 
each of these respective areas has yet to be thoroughly investigated in athletic populations. Elucidating the effects of whole 
cannabis, THC, and CBD is pertinent for both researchers and practitioners given the widespread use of these products, and 
their potential to interact with athletes’ performance and recovery.
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Key Points 
Use of cannabis, THC, and CBD by athletes for the 
purposes of improving performance and recovery is 
increasingly reported across different sports and levels of 
competition
Appropriate empirical evidence regarding the effects of 
cannabis use on sport performance is lacking. Under-
standing the short- and long-term effects of cannabis 
and THC on human performance in athletes will require 
well-controlled, athlete-specific research, with applied 
performance outcomes
CBD may have some promise for aiding athletes with 
recovery by improving sleep quality, pain, and mild 
traumatic brain injury
1 Introduction
The empirical case for or against cannabis use to aid ath-
letic performance remains tenuous. Despite evidence of 
long-standing human consumption over the ages [1], sci-
entific investigation into the effects of cannabis has been 
relatively limited, largely in part to challenges faced to 
investigate a drug that has a long global history of pro-
hibition and tight regulatory control [2, 3]. Despite can-
nabis remaining an illicit drug in a majority of countries 
and holding a place on the World Anti-Doping Agency’s 
(WADA) prohibited substance list, accounts of its use 
amongst competitive and recreational athletes abound 
[4–7].
Today, the global use of cannabis and formulations 
made of its derivatives are progressively more widespread 
as many nations relax laws around both medical and rec-
reational use. Cannabis has been noted as the second most 
consumed recreational substance, next to alcohol [8], and 
with such ubiquity and increasing belief of potential for 
health benefit, the enticement for uptake and use by ath-
letes is not surprising. While commonly used as a recrea-
tional drug outside the context of sport, evidence suggests 
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that athletes who use cannabis do so with the intent of 
enhancing performance (whether this is likely to occur or 
not), with factors such as sporting background, individual 
vs. team sport participation, competition level, sex, and 
demographic background further affecting predispositions 
to use [4–6]. A recent meta-analysis of 11 studies repre-
senting over 46,000 athletes of varying age and ability 
suggests that ~ 23% have used some form of cannabis in 
the past year [9].
Plants of the Cannabis genus contain over 100 genus-
specific molecules [10], known as phytocannabinoids: 
the two most studied being delta-9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD). THC is widely recognized 
for its psychotropic effects. The selective breeding and cul-
tivation of new cannabis strains for both recreational and 
medicinal use has commonly focused on THC, resulting in 
alterations to cannabinoid ratios and increases in relative 
THC concentration over time [11]. It is now understood 
that THC exerts a variety of physiological effects via the 
endogenous cannabinoid, or endocannabinoid, system. 
More specifically, THC acts as a partial agonist to the 
putative endogenous cannabinoid receptors type 1 (CB1) 
and 2 (CB2), which are located in a wide range of central 
and peripheral tissues [12, 13]. CBD, on the other hand, is 
devoid of psychotropic effects [11], and while it appears to 
have limited physiological influence through CB1 or CB2, 
it is believed to act at a number of other receptor targets 
and may modulate the effects of THC [13–15]. Given the 
unique effects of THC and CBD to elicit differing physi-
ological effects that could alter exercise performance or 
recovery, coupled with their differing status as legal or 
prohibited substances, there is a growing interest in scien-
tific evidence for a variety of purported uses. Furthermore, 
exercise itself may have unique interactions with the endo-
cannabinoid system which may modulate the effects of 
exogenous cannabinoids [16]. It is important to acknowl-
edge that cannabis contains many other molecules which 
could theoretically have physiological effects, and conse-
quently affect human performance; however, the effects 
of these less abundant cannabinoids and compounds are 
beyond the scope of this review.
Cannabis is most commonly consumed via inhalation of 
combusted plant material, colloquially referred to as smok-
ing, which leads to rapid uptake and effects [17]. Cannabi-
noids may also be consumed by ingesting cannabinoid-con-
taining food products, leading to delayed uptake (30–60 min 
post) with peak effects occurring between 1.5 and 3 h post-
consumption [18]. It should, however, be acknowledged 
that the pharmacology of THC and CBD may vary signifi-
cantly according to a variety of contextual factors, leading 
to a wide range of bioavailability and elimination rates, as 
reviewed elsewhere [19]. It is suggested that the effects 
of consumption, specifically the anxiolytic properties and 
muscle relaxing effects [4] are a highly sought-after effect 
for many athletes. Isolated CBD may also possess anxiolytic 
effects and is purported to have a variety of other beneficial 
effects such as improvements to sleep, exercise recovery, 
pain, anxiety, mood, and recovery from concussion [20]. 
These factors represent motivation for use amongst athletic 
populations, including professional athletes [20]. Despite the 
reported widespread use of whole cannabis, cannabinoid-
based food products, and isolated CBD amongst athletes 
who have intentions of affecting athletic performance and/or 
recovery, there is no clear consensus about the general effi-
cacy of use. At present, according to WADA, cannabis is in 
contravention of at least two of the three tenets of acceptable 
use in that it: has potential to enhance sport performance, 
represents a health risk to athletes, and violates the spirit of 
sport. Consequently, cannabis and all other cannabinoids 
(with the exception of CBD) are prohibited during the in-
competition phase. Amidst the current evidence this remains 
a controversial topic in the anti-doping realm [21].
While opinions regarding the efficacy of cannabis (and 
its constituent products) to meaningfully affect sport perfor-
mance remain split, cannabis demonstrates clear potential 
to perturb cardiovascular [22], respiratory [23], and cogni-
tive function [24]. However, in an era of evidence-based 
decision making, a paucity of trials explicitly examining the 
effects of whole cannabis, THC and CBD on varied exercise 
performance and recovery specific outcomes leaves a sig-
nificant vacuum in which decisions must be made. Notably, 
rulings about the suitability of use in the context of sport 
must simultaneously consider both the potential to alter per-
formance and the potential for adverse health effects, which 
may include serious cardiovascular events, amongst other 
dangers, which are discussed in detail elsewhere [25–28]. 
Amongst these issues are the effects that THC may have 
on alterations in motor control or decision making [29] but 
in many ways these factors are limited to the psychologi-
cal, as opposed to psycho-physiological, effects on perfor-
mance. Thus, this review focuses on the existing evidence 
for the physiological effects of cannabis, THC, and CBD 
consumption for exercise performance and recovery, while 
highlighting requisite areas of future research to progress our 
empirical understanding in the context of sport performance. 
Given the notable differences in the psychological and physi-
ological effects of THC and CBD, as well as the potential 
indications for use in the context of sport, CBD is discussed 
independently of whole cannabis and THC.
2  Cannabis, THC, and Exercise Performance
The topic of cannabis use and the specific effects of THC 
on human exercise performance have been considered previ-
ously [9, 21, 27, 30–36]. Perplexingly, despite there being 
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few new data generated over the past few decades, repeated 
interpretations of these data have led to vastly different 
conclusions, with reviews presuming: no benefit [30, 31], 
potential advantages [21] and predominantly an ergolytic 
effect [9, 32–34]. As such, we include a critical review of 
current work, and recognition of the knowledge gaps that 
must be filled to clarify the effect on human performance 
more specifically.
Compared to the empirical data on other performance 
related drugs and supplements, the evidence regarding can-
nabis and THC use is conspicuously lacking. While the vol-
ume of data is evidently sparse, it is also noteworthy that the 
most relevant literature was published 35–45 years ago, with 
little progress since. Further, there are important considera-
tions of study design and collection methods that limit our 
ability to meaningfully extrapolate findings for understand-
ing the potential effect of cannabis and THC use on sport-
ing performance in the current day. Amongst these factors 
are: a substantial increase in the typical dose of THC over 
time (increased between sixfold and tenfold [11]), evolv-
ing methods of consumption and recognition that timing of 
intake/uptake may influence physiological responses, and an 
improvement in our ability to quantify performance as physi-
cal work output. At the time of writing, we have identified 
ten studies that consider the effects of cannabis on human 
performance. Four are cross-sectional studies that charac-
terize the physical capacities of long-term cannabis users 
compared to non-using controls [37–40], and six involve the 
administration of cannabis or THC to participants prior to 
exercise [41–46]. Of these experimental studies, 50% were 
performed in persons with identified coronary artery disease 
or chronic obstructive pulmonary disease (COPD).
2.1  Chronic Cannabis Users
Even at a superficial level, there is value in understand-
ing whether individuals who habitually use cannabis dif-
fer in their ability to perform exercise from those who do 
not. Such investigations can shed light on the possibility 
of persistent performance effects of cannabis with long-
term use. However, while such research designs eliminate 
the need for logistically challenging studies that require the 
longitudinal administration of dosed cannabis, their cross-
sectional nature precludes the control of potential bias and 
cause-and-effect cannot be concluded. Of the existing data 
comparing cannabis users to non-users, there are no reported 
differences in aerobic fitness (VO2max), blood pressure, mus-
cular strength and endurance measures, work capacity, and 
perceived exertion [37–40]. In physically active cannabis 
users, there are no differences in anaerobic power, or mark-
ers of stress and inflammation [37, 39]. Notably, in all stud-
ies, participants had been asked to abstain from cannabis 
consumption for hours to days prior to testing in an attempt 
to avoid transient physiological effects from recent use, but 
this might not represent a normal functioning state for heavy 
users and may be confounded by potential interactions with 
withdrawal effects [47], which should also be considered 
in studies where cannabis is administered. The typical con-
cern about the potential for bias (e.g., self-selection to par-
ticipate) in cross-sectional studies must still be considered. 
Taken together, there is presently little evidence to suggest 
chronic cannabis use performed in isolation from training or 
competition exerts a great effect on any measure of physical 
performance in recreationally active participants.
2.2  Diseased
Exercise is a commonly used tool for the identification and 
elicitation of signs and symptoms of underlying cardiovas-
cular disease (CVD). While studies examining the com-
bined cardiovascular stress of exercise with cannabis use 
in persons with identified CVD offer select insight into the 
human ability to perform aerobic work, their widespread 
acceptance as concrete evidence of the effects of cannabis or 
THC on general or high-level human performance is likely 
misplaced. It is worth highlighting that these studies were 
never designed to specifically address these questions, and 
this fact appears to be commonly overlooked in the context 
of interpretation and application for sport.
The first study of cannabis and exercise was performed 
in patients (n = 10) with significant coronary artery dis-
ease (> 75% narrowing of coronary artery), with the onset 
of angina as a major endpoint [42]. Comparing exercise 
capacity after smoking cannabis or a cigarette placebo, both 
groups demonstrate a decrease in time to exhaustion. This 
effect was greater with cannabis use (48% vs 8.6%), pos-
sibly because of an increase in myocardial oxygen demand 
(rate-pressure product), a mechanism discussed in Sect. 3. 
It is worth noting that, according to the loading protocol 
described in the methods, even during the control condi-
tion participants were capable of only a 25 W power output 
and ≤ 25% of the test was performed at an increased work-
load of 50 W. For comparison, the modern professional male 
cyclist can sustain approximately 500 W for a similar dura-
tion of 120 s amidst hours of riding on consecutive days 
[48], highlighting the absurdity of using one population to 
predict effects in the other. The use of cannabis was also 
a novel stimulus amongst these participants. This work 
was confirmed by the same group using similarly diseased 
patients, and an equally low exercise stimulus and THC 
dosage (< 15 mg) the following year [45]. It is worth high-
lighting that these two studies commonly represent > 50% 
of the “performance” evidence cited in existing reviews 
to suggest an ergolytic effect of cannabis on performance. 
More recently, to explore the effects on breathlessness and 
exercise capacity, COPD patients consumed whole cannabis 
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(vaporized not smoked, 6.4 mg THC) prior to cardiopulmo-
nary exercise testing [46]. Cannabis was reported to have 
no impact on any cardiorespiratory responses, nor exercise 
time, and it is worth noting that exercise lasted < 5 min. 
Importantly, this group of patients had advanced COPD 
and fitness that was approximately 10% of what would be 
expected for a healthy (non-athletic) control.
2.3  Healthy
Steadward and Singh published the first investigation—and 
to date one of only three studies—in healthy participants 
(n = 20), exploring the effects of cannabis on cardiorespi-
ratory responses to exercise, physical work capacity, and 
strength [41]. After smoking a moderate dose of THC 
(18.2 mg), participants showed no apparent effect on hand-
grip strength, but submaximal work capacity on a cycle 
ergometer decreased. Importantly, this decrease was con-
comitant with and inseparable from an increase in sub-
maximal heart rate (HR) in the cannabis group. In papers 
reporting this research as evidence of an ergolytic effect of 
cannabis, it is commonly ignored that the test of physical 
performance, known as the  PWC170—a commonly used test 
from this time, is a submaximal test for which performance 
is estimated based on the work output at a given HR (i.e., 
physical work capacity at a heart rate of 170 bpm). While 
the linear relationships between HR and either VO2 or power 
output make this a useful measure of capacity under normal 
circumstances [49, 50], this relationship can no longer be 
trusted as accurate after the administration of a drug that 
specifically alters the variable that is being controlled for. It 
should be surprising to no one that when submaximal HR 
is artificially inflated—and power is measured at a clamped 
HR—that the work output will necessarily be lower. Nota-
bly, there are examples of other definitively ergogenic sub-
stances, such as ephedrine and caffeine, that increase sub-
maximal HR and improve endurance performance [51, 52]. 
Thus, it is inadvisable to conflate the tachycardic effects 
of cannabis consumption with an ergolytic effect. Ava-
kian et al. [43] similarly followed-up with a submaximal 
exercise study (40–50% VO2max) with individuals (n = 6), 
habituated to cannabis use. While no effects of cannabis use 
were evident on blood pressure, ventilation (V ̇E) or V ̇O2, a 
sustained tachycardic HR response was reported. However, 
no true measures of maximal exercise performance were 
recorded and the extrapolation of a submaximal effect on 
HR at 50% of capacity to exercise performance in a com-
petitive situation requires large, unsupported assumptions of 
equivalency. Despite the results of this work often being ref-
erenced regarding exercise performance, the authors them-
selves conclude that “…the significance of their observation 
is not established”. Interestingly, all subjects were able to 
identify the placebo from the low dose (7.5 mg) THC condi-
tion during exercise, leaving the possibility that psychologi-
cal factors could modify exercise behaviors, but this has yet 
to be an empirically tested outcome, nor has blinding been 
effectively performed. This is an important consideration for 
future research examining the psycho-physiological effects 
of cannabis in a more targeted performance setting.
The final, and most specific performance work to date, 
is the only study to examine healthy participants exercis-
ing to maximal capacity. In this work, Renaud and Cormier 
[44] had participants (n = 12) perform progressively more 
challenging workloads (16.4 W each min) until “leg failure” 
both under control conditions and after having consumed 
cannabis (1.7% THC) dosed at 7 mg of dried cannabis per 
kg body weight. At maximal exercise, no differences were 
found in HR, V ̇E, V ̇O2 or volume of exhaled carbon dioxide 
(VĊO2); suggesting that despite the submaximal tachycardic 
response, physiologic responses at maximal workloads were 
not different after cannabis consumption [44]. Examina-
tion of submaximal through maximal work clearly shows a 
diminishing difference between placebo and cannabis groups 
as exercise intensity is increased. At workloads greater than 
80% of maximal effort no differences existed, calling into 
question the implications of previous submaximal work for 
modelling effects of performance, especially as V ̇O2max is 
not affected [44]. The most lauded finding from the work 
of Renaud and Cormier [44] was the fact that there was a 
significant difference in exercise duration, with cannabis 
exposure decreasing time to exhaustion. While the data do 
indeed support this finding, examination of the exercise test-
ing protocol demonstrates that this difference (16.1 ± 4 vs 
15.1 ± 3 min) represents an average difference of a single 
one-minute stage, and 100 kpm/min, or about 16 W. It is 
unclear if this was truly a scaled linear variable (time), or 
if it was an ordinal variable—such that participants were 
encouraged to finish each stage with only finished stages 
being counted. In either case, the implications of such a 
small magnitude change on this type of staged test are ques-
tionable. As this is truly the only investigation of exhaus-
tive performance in healthy participants, the methodological 
ambiguity and debatable practical validity of the findings 
indicate that further work is warranted.
2.4  Knowledge Gaps and Recommendations
There is a paucity of valid exercise studies designed to 
specifically investigate the effects of cannabis and THC on 
human exercise capacity and performance. It is noted that 
physiological capacity and performance are interrelated, but 
not equivalent. Factors such as an athlete’s perception (e.g., 
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time, pain, appropriate pacing strategies) and motivation 
ultimately affect performance and could also be altered by 
cannabis or THC, but have not been investigated. Healthy 
subjects who have varied levels of fitness and habituation 
to cannabis need to be studied, with further consideration 
of the methods of cannabis intake and the pharmacokinet-
ics that dictate the time of peak effects. Dose–response 
curves should be developed, with varied exercise modes 
(e.g., cycling, running, strength assessments), intensities 
(i.e., submaximal, maximal, sprint-power based), durations 
(e.g., up to and including ultra-endurance events) and mod-
els of performance (time to exhaustion, time trial, power 
output). Improved technologies, including electronically 
braked ergometers and breath-by-breath indirect calorimetry, 
now allow research to move beyond the incremental-stage 
graded exercise test. These contemporary technologies and 
best practices should be employed to increase the sensitivity 
and validity for tests of physical capacity and performance.
3  Cannabis and Systems‑Level 
Cardiorespiratory Physiology
While the bona fide effects of cannabis on athletic perfor-
mance are limited by an incomplete evidence-base with low 
ecological validity for athletes, the physiological actions of 
cannabis and THC offer important insight into perturbations 
of cardiorespiratory homeostasis through which cannabis 
may interact with performance. Studies from these areas 
have generally been considered separately (for reviews of 
cannabis and performance see [9, 21, 27, 30–36]; for reviews 
of cardiovascular effects of cannabis see [22, 25]) with no 
comprehensive integration. As exercise clearly requires a 
coordinated and integrated response from multiple physi-
ological systems, this is a notable shortcoming.
Studies administering cannabis and isolated THC to 
healthy individuals have revealed a wide range of cardio-
vascular effects, including: changes in heart rate [41–45, 
53–85], cardiac function [55, 59, 64, 75, 76, 79, 83], blood 
pressure [41, 42, 53, 57, 59–61, 63–65, 75–78, 83], orthos-
tatic hypotension [53, 60, 80], ventilatory sensitivity to car-
bon dioxide [61], and limb blood flow [53, 78, 85].
Transient sinus tachycardia is a commonly reported dose-
dependent effect of cannabis and THC consumption [55, 
68, 70, 72, 82, 83]. As noted for the performance literature, 
this effect persists during submaximal exercise, resulting in 
a greater rate-pressure product at a given exercise intensity, 
indicative of increased myocardial oxygen demand [86]. 
When consumed via smoking, this elevated myocardial oxy-
gen demand associated with cannabis consumption could 
be exacerbated by reduced oxygen supply consequent to the 
inhaled carbon monoxide present in cannabis smoke [87]. 
The disruption of the myocardial oxygen supply/demand 
relationship likely explains why myocardial ischemia is 
precipitated by cannabis smoking in coronary heart disease 
patients [42, 45]. It is worth noting this phenomenon may 
not be unique to cannabis smoking, as placebo and tradi-
tional cigarette smoking in these same studies induced an 
attenuated, but still significant, reduction in time to angina 
compared to cannabis, likely due to the fact that all smoking 
involves the inhalation of carbon monoxide and hydrocar-
bons but does not produce the cannabis specific tachycardic 
effect.
The acute effects of cannabis and THC consumption 
on blood pressure are more variable, with potential impli-
cations for perfusion during exercise. Investigators have 
reported increases in systolic and diastolic pressure [41, 
42, 53, 59, 61, 64, 65, 76–78, 83], reductions in blood 
pressure [60, 63], or no changes in blood pressure [43, 
58, 59, 62, 63, 73–75, 81, 88–90] following cannabis or 
THC consumption. Unlike HR, it appears that pressure 
responses during exercise are not affected following a 
single instance of cannabis consumption [43]. However, 
if THC is persistently administered in high doses (up to 
210 mg/day for multiple weeks) blood pressure responses 
to exercise are altered; with an attenuation of the rise in 
systolic blood pressure, and an exaggeration of the reduc-
tion in diastolic blood pressure [77]. Thus, the timing 
and quantity of THC dose may also influence the pres-
sor response to exercise. The reported increase in limb 
blood flow following cannabis consumption [53, 78, 85] 
could also partially explain the varied effects on pressure, 
but limb blood flow following cannabis and THC con-
sumption has only been examined at rest. During exercise 
performance, cannabis induced increases in flow could be 
relevant given limited evidence that suggests that muscle 
blood flow may, to some degree, limit maximal exercise 
capacity [91]. Further studies are needed to reach conclu-
sions about how these hemodynamic effects of cannabis 
and THC interact with performance outcomes.
Echocardiographic studies have generated equivocal find-
ings with respect to cardiac function, reporting both reduced 
systolic function [59] and increased left ventricular tissue 
velocity [64, 76] following cannabis smoking. Whether the 
myocardial effects of cannabis and THC impact exercise per-
formance remains unclear, owing largely to uncertainty over 
whether the effects observed at rest persist during exercise—
and if so, the extent of functional consequences. Employing 
modern tests of cardiac function and imaging techniques, 
such as stress echocardiography [92] or magnetic resonance 
imaging [93], is required to fill this knowledge gap, as imag-
ing and analysis capabilities have evolved substantially since 
the publication of the aforementioned seminal works. The 
importance of cardiac mechanics (such as left ventricular 
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strain, torsion and twist) for understanding cardiac function 
is increasingly recognized [94, 95]; yet to date only two stud-
ies have examined these variables in chronic cannabis users 
[96, 97], and no studies have examined the acute effects of 
cannabis or THC.
A large body of evidence from in-vitro and animal models 
indicates that the mechanisms through which cannabis and 
THC elicit cardiovascular effects are likely vast and many 
could be relevant to exercise performance (for review, see 
[25]). In humans the cardiovascular effects of THC and can-
nabis appear to be largely mediated through autonomic nerv-
ous mechanisms and the endocannabinoid system. Treatment 
with beta-adrenergic blockade prior to THC or cannabis 
administration markedly blunts tachycardic [65, 75, 84, 85] 
and pressor [65, 75] responses, increases in limb blood flow 
[78, 85], and alterations to systolic time intervals [75]. Thus, 
it appears that the cardiovascular effects of THC and can-
nabis are mediated at least partially through the sympathetic 
nervous system. Beta-adrenergic blockade in combination 
with anti-cholinergic agents augments the effects of THC 
and cannabis on HR and blood pressure [75, 77, 78, 85]. 
The endogenous cannabinoid system also appears able to 
facilitate certain cardiovascular effects of THC, suggesting a 
degree of redundancy. Following the discovery of the endo-
cannabinoid system and identification of CB1 in cardiovas-
cular tissues [98, 99], investigations of human participants 
revealed that inhibition of CB1 also ablates the tachycardic 
effects of cannabis [69, 70, 72–74, 89, 100]. Despite these 
putative mechanisms through which cannabis and THC exert 
cardiovascular effects, cannabis contains hundreds of chemi-
cal compounds, including over 100 phytocannabinoids [10]. 
Thus, it should be accepted that the physiological effects of 
cannabis cannot be solely attributed to THC until further 
investigations examine the many constituents of the plant.
Given the inseparable links of the cardiovascular and 
respiratory systems to support aerobic exercise perfor-
mance, the effects of cannabis and THC consumption on 
respiratory function must be considered. Epidemiological 
analyses of the respiratory effects of chronic cannabis use 
have failed to show a clear linear relationship between 
cannabis smoking and reduced pulmonary function [101], 
and generally only demonstrate reduced function with very 
heavy cannabis use [102]. Thus, it may be that exercise 
capacity is, similarly, only impacted negatively with heavy 
cannabis use. Cross-sectional data comparing VO2max, 
work capacity, pulmonary function, and strength and 
endurance outcomes have consistently demonstrated no 
differences between young cannabis users and non-users 
[37–40]; however, no comparison has been made between 
non-users and longtime heavy users.
The acute and transient effects of cannabis and THC on 
respiratory function during exercise have received little 
attention. Of the two studies performed in healthy indi-
viduals, one revealed no differences in respiratory function 
[41], and the other demonstrated an increased capacity to 
expire forcefully  (FEV1) after exercise [44]. Alterations 
in flow are most likely related to the reported broncho-
dilator effects of THC [103]. Theoretically, the ability 
of THC to induce bronchodilation in healthy and asth-
matic participants [104] provides a potential mechanism 
through which cannabis could influence performance, as 
bronchodilating substances have previously been used 
by athletes for purported ergogenic effects [105]. How-
ever, the ergogenic potential of this bronchodilator effect 
remains to be confirmed, and it is notable that COPD 
patients experienced no improvement in exercise capacity 
or respiratory function following inhalation of vaporized 
cannabis [46]. It must also be considered that a number 
of bronchodilating substances are currently permitted for 
use in sport by WADA [106], and the evidence support-
ing the ergogenic effects of bronchodilating substances is 
tenuous [107]. Another intriguing observation is that THC 
appears to alter ventilatory sensitivity to carbon dioxide 
[61]. At present, it is not clear whether this effect occurs, 
or is consequential, during exercise.
There currently exists a substantial body of evidence 
demonstrating that consumption of cannabis leads to 
numerous systemic cardiorespiratory effects at rest, largely 
due to the actions of THC. Despite increasing use of rec-
reational and medicinal cannabis, it remains unclear which 
effects persist during dynamic exercise, and how they 
might impact performance. Understanding these effects 
is not only necessary to determine how cannabis impacts 
performance across athletic disciplines, but also to inform 
decisions regarding the safety and regulation of cannabis 
use in both athletic and non-athletic populations.
3.1  Knowledge Gaps and Recommendations
The effects of cannabis and THC on rudimentary cardi-
orespiratory physiology in resting humans are well charac-
terized; however, both cannabis potency and investigative 
research capabilities have increased dramatically since many 
of these studies were initially performed, without concomi-
tant study. The independent effects of inhaling combusted 
plant material versus the effects of cannabis and THC are 
incompletely understood, both at rest and in an exercise con-
text. For future work to successfully characterize the effects 
of cannabis and THC on performance, underlying physi-
ological effects must be rigorously investigated before, dur-
ing, and after exercise.
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4  CBD and the Elite Athlete
While whole cannabis is commonly used across the globe 
for both recreational and medicinal purposes [9] in many 
countries it remains an illicit drug [108], and from an ath-
letic perspective it is currently prohibited (in competition) 
by WADA. However, one of the major phytocannabinoids 
within cannabis, CBD, was specifically removed from the 
WADA prohibited list in 2018 and as a consequence its inter-
est in sport has grown exponentially. Interest in CBD is also 
largely driven by the fact that the l-isomer of CBD originat-
ing from cannabis plants does not have psychotropic prop-
erties, although some synthetic analogs might [109]. The 
use of CBD in sport has recently been reviewed extensively 
[110]. The individual phytocannabinoid derivatives from the 
cannabis plant face discrepant restrictions by some sporting 
governing bodies and WADA [106]. Of all the phytocan-
nabinoid derivatives, the only constituent absolutely legal 
from a WADA perspective is CBD. All other phytocannabi-
noid derivatives are prohibited per se except THC which is 
considered a threshold substance, meaning that only con-
centrations > 150 ng/ml in urine result in an anti-doping rule 
violation (ADRV) [111]. It is also important to stress that 
the legislative regulation of CBD itself is somewhat complex 
and it is, therefore, vital that athletes are aware of the spe-
cific country, and in the case of the US, state specific legisla-
tion before considering the potential for CBD use in sport. 
Despite this lack of clarity surrounding the precise legality 
of CBD commerce and consumption, supplementation in 
athletic populations has grown due to its purported effects 
on athletic performance and recovery [9, 20].
4.1  Sleep and Anxiety
Appropriate sleep is widely accepted as an integral com-
ponent of the recovery process in athletes (for review see 
[112]). Professional athletes have previously reported sub-
optimal sleep quantity [113] and quality [114]. Indeed, dis-
turbances in sleep can be a consequence of several mecha-
nisms including pre-game supplementation [115], the time 
of competition [116], implications of long-haul travel [117], 
and anxiety associated with competition [118–121]. It is, 
therefore, understandable that athletes supplement products 
such as CBD, with the aim to improve sleep efficiency and 
provide anxiolytic properties [122], despite associated evi-
dence being limited to clinical research as opposed to within 
elite athlete cohorts.
Any potential positive effects of CBD on sleep are pri-
marily limited to diseased populations, such as sufferers 
of Parkinson’s disease [123] and post-traumatic stress dis-
orders [122], with randomized controlled trials in human 
participants somewhat limited. However, Carlini & Cunha 
reported that CBD supplementation (160 mg) significantly 
increased sleep duration in individuals reporting difficulties 
in both sleep onset and quality [124]; however, conclusions 
were limited to perceived/subjective measures as opposed to 
objective polysomnographic data. More recent research from 
Linares and colleagues showed no significant effects of CBD 
(300 mg) on either subjective sleep quality or objective poly-
somnography measures, though it is important to note that 
although the latter utilized a higher dose of CBD, partici-
pants were healthy and not experiencing any reported sleep 
disturbance [125]. As such, although CBD shows promise in 
sleep quantity and quality, well-designed randomized con-
trolled studies in athletic populations are required to deter-
mine the exact, if any, situation in which CBD may provide 
this sleep (and thus recovery) enhancing effect.
4.2  Pain, Inflammation, and Muscle Function
Exercise induced muscle damage (EIMD) is a well-estab-
lished phenomenon following athletic activity (for review 
see [126]). Throughout congested competition schedules and 
particularly damaging exercise bouts [127], pain and recov-
ery management is often modulated via non-steroidal anti-
inflammatory drugs (NSAIDs) and, in some cases, opiates 
[128]. However, in addition to the adaptation blunting effect 
of NSAIDs [126], chronic consumption has the potential to 
induce several adverse health effects [129]. It is, therefore, 
unsurprising that in a recent study of elite rugby players, 
26% of players had previously experimented, or were cur-
rently using CBD supplements, which have been shown to 
have mild-moderate adverse effect profiles in humans [130, 
131]. That said, as a result of CBD’s metabolism by the 
CYP3A4 and CYP219 enzymes it can potentially increase 
drug-drug interactions with other compounds metabolized 
by the same enzymes, subsequently increasing potential 
adverse effects profiles [132]. In this study, ~ 80% of rugby 
players cited pain management as their primary motive for 
experimenting with CBD [20]. This high prevalence of use 
was in spite of the current lack of an evidence-base for the 
efficacy of supplementation, and risks of potential ADRVs 
[20, 133]. Interestingly, despite the high number of rugby 
players taking CBD for pain modulation, only 14% of rugby 
players reported any beneficial effect [20]. These findings 
may be as a result of the disparity in the reported doses 
consumed by athletes [20], especially as higher doses may 
be required to offer anti-inflammatory effect in humans. Low 
vs. high doses of CBD (10 vs. 500 mg/day) have shown 
differing pain alleviating results (non-significant vs. signifi-
cant) in patients experiencing high levels of gastrointestinal 
inflammation [134, 135], with higher dosages, although sig-
nificantly relieving pain, also resulting in issues within the 
gastrointestinal tract or central nervous system. It is worth 
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noting that the population of this study already had gastro-
intestinal issues, which may, in part, explain these increased 
adverse effects [135].
Despite the widespread inclusion of strength train-
ing amongst high-level athletes, studies investigating the 
effects of CBD supplementation on resistance exercise are 
extremely limited. To date, only two preliminary studies 
are available with varying research designs, and equivocal 
findings. For example, 150 mg day of oral CBD (2 × 75 mg 
doses given immediately post, 24 and 48 h following a mus-
cle-damaging protocol) had no beneficial effects on either 
muscle function or perceived soreness in untrained males 
(n = 13) [136]. The only other available data on CBD and 
muscle soreness in an athletic context are limited to a sin-
gle abstract from a conference communication [137]. This 
study assessed muscle damage (via creatine kinase [CK]) 
following a single bout of resistance exercise and suggested 
that CBD supplementation (60 mg/day) attenuated the acute 
increases in CK. However, alongside the proposed reduction 
in muscle damage, there were also reductions in strength 
within 24 h of supplementation. It is important to consider 
that neither of these studies assessed blood or urine can-
nabinoid concentrations and the equivocal data could be 
related to the efficacy of the supplementation protocols 
with major differences in the actual dose of CBD, number 
of days supplemented, and route of administration. Collec-
tively, the evidence to date on the effects of CBD on mus-
cle function following damaging exercise could be, at best, 
described as ‘in its infancy’ and, therefore, it is not possible 
to reach any form of conclusion as to the efficacy of CBD 
for muscle recovery. Research is now required, including 
pharmacokinetic data, measures of blood cannabinoids, 
and dose–response data to fully explore if CBD is able to 
attenuate muscle damage and/or enhance recovery follow-
ing exercise.
4.3  Neuroprotection and Traumatic Brain Injury
Concussion is a type of mild traumatic brain injury (mTBI) 
[138] which may occur following a rapid deceleration or 
rotational force applied to the brain [139]. These biomechan-
ical mechanisms of injury are a particular concern in col-
lision and combat sports such as rugby union [140], rugby 
league [141] American football [142, 143], as well as boxing 
and mixed-martial arts [144]. Several acute side-effects may 
be experienced during concussion including headaches, cog-
nitive impairments, sleep disruption, and behavioral changes 
[145]. Moreover, long-term effects of concussion can 
include behavioral changes leading to aggressive episodes, 
anxiety, and depression [146]. Despite the exact mechanisms 
by which this may be achieved being unconfirmed, CBD has 
been proposed to offer a protective benefit in athletes who 
are “at risk” of mTBI in sport [147]. Suggested mechanisms 
include the anti-inflammatory nature of CBD [148, 149], 
anandamide uptake and enzymatic hydrolysis [150], and/
or a decrease in adenosine reuptake [151]. To date, a single 
murine study has investigated the effects of CBD on mTBI 
[147]. In this study the authors concluded that chronic CBD 
administration (equating to ~ 51 mg/day when converted to a 
human equivalent dose [152]) reduces dysfunctions relating 
to the anxious, aggressive and depressive behaviors often 
exhibited following mTBI. Given the severe consequences 
of mTBI to health, coupled with the proposed neuroprotec-
tive potential of CBD, it is imperative that additional inves-
tigation in this area be completed in humans to understand 
the mechanisms by which CBD may offer a neuroprotective 
benefit to athletes who are at risk of mTBI.
4.4  Knowledge Gaps and Recommendations
As a consequence of the complicated legislative status of 
CBD, research in-vivo is less common than for other ergo-
genic supplements regularly consumed by athletes. Whilst 
many CBD products available for purchase without prescrip-
tion claim to have negligible, or even 0% THC, these claims 
are sometimes unfounded with a recent study suggesting that 
only 3 of a selected 25 CBD products were within ± 20% of 
claims made on their respective containers [153]. Moreover, 
many CBD products that are THC free still contain other 
cannabinoids, which are prohibited by WADA, and detec-
tion may result in ADRVs. Indeed, as THC can be stored in 
fat tissue [154], blood and urine metabolites may peak fol-
lowing specific periods of lipolysis inducing exercise [154] 
or fasting [155]. When considering CBD products athletes 
should also ensure that the L-isomer is the molecule con-
tained, and be aware of the potential presence of other CBD 
analogs, which could possess psychotropic properties that 
may not be desired [109]. It is also important to consider 
that where CBD has been suggested as the root cause of sig-
nificant findings, there may in fact be an ‘entourage effect’ 
as other cannabinoids may be present [156]. From a safety 
perspective, despite being reported to have a reasonably 
low adverse effects profile, there appear to be significant 
drug metabolism interactions, as CBD is metabolized by 
CYP450 isoforms 2C19 and 3A4 [157, 158]. Approximately 
60% of clinically prescribed medications are metabolized by 
CYP3A4 and as a consequence there are suggestions that 
CBD can increase the adverse effects profile of standard 
medications such as clobazam used to treat epilepsy [130]. 
Subsequently, future research should investigate the efficacy 
of CBD in its therapeutic role in pain and recovery manage-
ment, sports-related anxiolytic and sleep promoting effects, 
and examine drug interactions and side effect profiles of 
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CBD supplementation. It is essential that studies begin to 
further investigate the mechanistic properties of CBD (and 
any ‘entourage effect’), as well as explore translatable mech-
anistic findings in-vivo.
5  Conclusions
Cannabis and individual cannabinoids have a clear capacity 
to affect certain facets of human physiology; however, the 
applicability of such physiological perturbations to affect 
improvements in the health, performance, or recovery of 
athletes remains incomplete owing to large knowledge gaps 
and low-quality existing evidence stemming from substan-
tial barriers to conducting high quality cannabis research 
[2, 3]. Herein, we have provided an overview of the existing 
evidence and areas for future research. Unlike CBD, can-
nabis and THC are prohibited by WADA in-competition, 
and while the cardiorespiratory effects at rest of cannabis 
and THC are well described, both the short- and long-term 
effects on the human capacity for exercise require well-con-
trolled, athlete-specific research, with applied performance 
outcomes. Additional work will be required to understand 
the dose–response of these effects, accounting for methods 
of consumption, timing around exercise and cannabinoid 
concentrations. Such data are essential for weighing the evi-
dence for or against prohibition both in and out of competi-
tion. The use of CBD by athletes is likely more relevant to 
recovery during training and while in competition. CBD may 
have some promise for improving athlete pain and recovery 
through a number of potential mechanisms, although evi-
dence to support this to date is extremely limited. Moreover, 
the use of CBD requires prudent attention to local regula-
tions and contamination with prohibited cannabinoids could 
trigger doping violations.
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